Jump to Topics

Soon, a blood test may spot Alzheimer’s early

Soon, a blood test may spot Alzheimer’s early

A new blood test developed by US researchers may fulfil a long-felt need to detect Alzheimer’s many years before the symptoms manifest. It may also benefit other diseases.
Health care worker collecting blood from an elderly woman
Representational image | Shutterstock

Early diagnosis of Alzheimer’s disease has eluded researchers and physicians alike for many years. This has led many to pursue development of improved tests to detect the mind-crippling condition before its clinical symptoms show.

A recent study by University of Washington (UW) researchers demonstrates a way to catch the abnormal proteins that were so far found only in advanced stages in people having Alzheimer’s.

The researchers caught the proteins through a simple blood test that they developed. This test may now be refined to routinely enable diagnosis of Alzheimer’s much earlier than at present.

One of the hallmarks of Alzheimer’s is the presence of protein clumps in the brain that have evaded detection until the condition has advanced. The clumps are made of a protein called amyloid-beta, whose structure gets altered and leads to the formation of amyloid beta oligomers. These toxic oligomers are typically seen in later stages of Alzheimer’s when they lead to the death of brain cells.

Damage undetected for 10-20 years

“Toxic oligomers are estimated to be doing damage for 10-20 years before the advent of symptoms” senior author of the study, Valerie Daggett, a professor of bioengineering at UW, tells Happiest Health.

While there is no solution yet to stop or reverse conditions such as Alzheimer’s, efforts are being made to detect the problem early so that effective interventions can be used to slow the progression of Alzheimer’s.

“The process to diagnose a patient and get referrals to dementia experts can take years. It’s important to provide a timely diagnosis and equally important to be able to rule out Alzheimer’s disease so that other potential cases of cognitive impairment can be investigated and potentially treated,” says Daggett.

Spot on with control group

For their study, the researchers designed a laboratory test called SOBA or soluble oligomer binding assay. It detected the presence of toxic oligomers in the blood of people diagnosed with Alzheimer’s as well as in individuals in the control group who did not show cognitive impairments.

In a follow-up a few years later, 10 individuals in the control group in whom SOBA had detected toxic oligomers showed cognitive impairments consistent with early signs of Alzheimer’s disease.

“What clinicians and researchers have wanted is a reliable diagnostic test for Alzheimer’s disease — one that can detect signs of the disease before cognitive impairment happens. That’s important for individuals’ health and for all the research into how toxic oligomers of amyloid beta go on and cause the damage that they do,” says Dr Daggett. “What we show here is that SOBA may be the basis of such a test.”

Caught in a `bind’

The SOBA test works by using the properties of amyloid beta oligomers to form a structure called an alpha sheet. This novel structure is not something that occurs in nature and binds itself to other alpha sheet structures.

Dr Daggett and team decided to make a synthetic form of the alpha sheet so that it could bind itself to oligomers found in blood and cerebrospinal fluid.

“We believe that SOBA could aid in identifying individuals at risk or incubating the disease, as well as serve as a readout of therapeutic efficacy to aid in development of early treatments for Alzheimer’s disease,” Dr Daggett says in a statement.

Test may benefit other conditions

She adds that the potential for a test like SOBA lies in helping people to get access to drugs like Lecanemab. This is an investigational drug which has been showing encouraging results in delaying cognitive decline in Alzheimer’s cases. Dr Daggert says it might be available to people with Alzheimer’s in the not-too-distant future.

Dr Daggett and her team are currently working with a company to develop SOBA as a diagnostic test for Parkinson’s, Type 2 diabetes and other conditions that show similar formation of the alpha structure.

Their goal is to neutralise the toxic oligomers and provide immediate treatments that can modify the conditions early.


Share Your Experience/Comments

Leave a Reply

Your email address will not be published. Required fields are marked *



Some couples consciously decide not to have children despite familial and social expectations, wanting to make the best of their relationship. Children should be had for their own sake, says psychotherapist Tasneem Nakhoda
Insufficient consumption of heart-healthy foods can affect cardiovascular health. Experts discuss beneficial dietary choices
Physical activity improves the quality as well as duration of sleep. But exercising too close to bedtime is not advisable




Opt-in To Our Daily Newsletter

* Please check your Spam folder for the Opt-in confirmation mail

Opt-in To Our
Daily Newsletter

We use cookies to customize your user experience, view our policy here

Your feedback has been submitted successfully.

The Happiest Health team will reach out to you at the earliest